Chonluten 20 mg

Chonluten 20 mg – Peptide Hubs

Chonluten is a synthetic short-chain peptide developed for use in respiratory and immune system research. Derived from bronchial mucosa regulatory peptides, Chonluten is designed to support tissue regeneration, modulate local immune responses, and reduce inflammation within the lungs and airways. The 20 mg lyophilized format from Peptide Hubs offers researchers a stable, high-purity tool for experimental use in pulmonary and immune health studies.

What Is Chonluten?

Chonluten belongs to the peptide bioregulator family and has been studied in models of chronic obstructive pulmonary disease (COPD), bronchitis, asthma, allergic inflammation, and post-viral lung repair. It supports the normalization of bronchial epithelium function and has shown promise in balancing cytokine profiles and reducing inflammation markers in preclinical testing.

Lab Test Result

Mechanism of Action

Chonluten functions at the epigenetic level by influencing DNA transcription processes in cells of the bronchial mucosa. It supports the restoration of cellular function, reduces chronic inflammation, and promotes immunological stability. For further scientific reference, see this NIH publication on short peptides and tissue regulation.

Applications in Research

Chonluten is primarily used in studies focusing on:

• Respiratory tract recovery post-infection
• Immune system modulation during chronic inflammation
• Support in bronchial epithelium regeneration
• Experimental asthma and COPD models

In some advanced respiratory recovery protocols, researchers stack Chonluten with Bronchogen 20 mg for enhanced pulmonary effects, or with ARA-290 to control inflammation while supporting vascular repair.

Suggested Experimental Use

• Dose: 10–20 mg per day
• Route: Subcutaneous or intranasal administration depending on the study
• Cycle Length: 10–20 days, based on the respiratory model

Peptide Stacking Options

Chonluten is often combined with other peptides for synergistic support in respiratory and systemic recovery:

• Semax – for neuro-immunomodulatory effects
• Cartalax – to aid connective tissue recovery in thoracic structures
• B7-33 – for anti-fibrotic effects in pulmonary studies

Safety and Legality

Chonluten has shown a strong safety profile in non-human models. It is non-hormonal, non-androgenic, and does not interfere with the endocrine system, blood pressure, or liver enzymes. Like all Peptide Hubs products, Chonluten 20 mg is sold exclusively for laboratory and research use and is not approved for human consumption.

Regulatory Notes

To stay updated on peptide bioregulator research and regulatory status, consult the ClinicalTrials.gov database.

Frequently Asked Questions